Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Riley, Jezia (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300, C530S330000, C530S331000, C548S146000, C548S215000, C548S333500, C548S335100
Reexamination Certificate
active
06858577
ABSTRACT:
The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
REFERENCES:
patent: 4977153 (1990-12-01), Louis et al.
patent: 5439906 (1995-08-01), Bock et al.
patent: 5530026 (1996-06-01), Gaudreault et al.
patent: 6017890 (2000-01-01), Hoekstra et al.
patent: 2011222 (1990-03-01), None
patent: 0 385 850 (1990-09-01), None
patent: WO 9214750 (1992-09-01), None
patent: WO 9318026 (1993-09-01), None
patent: WO 9900357 (1999-01-01), None
patent: WO 9933798 (1999-07-01), None
patent: WO 9942475 (1999-08-01), None
U.S. Appl. No. 09/603,229, McComsey et al.
U.S. Appl. No. 09/599,826, Zhang et al.
U.S. Appl. No. 09/603,338, Zhang et al.
Thrombin Receptor (PAR-1) Antagonists, Heterocycle-Based Peptidomimetics of the SFLLR Agonist Motif, William J. Hoekstra et al., Bioorganic & Medicinal Chem Ltrs 8, pp. 1649-1654, Jul. 7, 1998.
Development of Potent Thrombin Receptor Antagonist Peptides, M.S. Bernatowicz et al., J. Med. Chem vol. 39, pp. 4879-4887, Dec. 6, 1996.
“Heterocycle-Peptide Hybrid Compounds, Aminotriazole-Containing Agonists of the Thrombin Receptor (PAR-1)”, David F. McComsey et al., Bioorganic & Medicinal Chemistry Letters 9 (1999), pp. 1423-1428.
“Design, Synthesis, and Structure-Activity Relationship for a Series of Factor XA Inhibitors Containing the Benzimidazoone Nucleus as a Central Template”, Charles K. Marlowe et al., Medicinal Chemistry, COR Therapeutics, Inc., Abstract.
“Novel Indole-Based Peptidomimetics as Potent Thrombin Receptor (PAR-1) Antagonists”, Han Cheng Zhang et al., The R.W. Johnson Pharmaceutical Research Institute, Abstract.
“Approaches to the Synthesis of Ureapeptoid Peptidomimetics” John A.W. Kruijtzer et al., Tetrahedron Letters, vol. 38, No. 30, pp. 5335-5338, 1997.
“Cloning and Characterization of Human Protease-Activated Receptor 4”, Wen-Feng Xu et al., Proc. Natl. Acad. Sci. USA, vol. 95, Jun. 1998, pp. 6642-6646.
“Molecular Cloning of a Proteinase Activated Receptor”, Sverker Nystedt et al., Proc. Natl. Acad. Sci. USA, vol. 91, Sep. 1994, pp. 9208-9212.
“Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor”, David T. Hung, et al., The Journal of Cell Biology, vol. 116, No. 3, Feb. 1992, pp. 827-832.
Thrombin Receptor Activation Causes Rapid Neural Cell Rounding and Neurite Retraction Independent of Classic Second Messengers, Kees Jalink et al., The Journal of Cell Biology, vol. 118, No. 2, Jul. 1992, pp. 411-419.
“Thrombin-Induced Expression of Endothelial. P-Selectin and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion”, Yasuo Sugama et al., The Journal of Cell Biology, vol. 119, No. 4, Nov. 1992, pp. 935-944.
“Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, Thien-Khai H. Vu et al., Cell, vol. 64, Mar. 1991, pp. 1057-1068.
“Response of a Human Megakaryocytic Cell Line to Thrombin: Increase in Intracellular Free Calcium and Mitogen Release”, Cindy L. A. Jones, et al., Biochemica et Bioophysica Acta. 1136, 1992, pp. 272-282.
“Thrombin Effects on Osteoblastic Cells—II. Structure-Function Relatoinships” Dimitris N. Tatakis et al., Biochemical and Biophysical Research Communications, vol. 174, No. 1, Jan. 1991, pp. 181-188.
“Condensed Heteroaromatic Ring Systems—XIII. One-Step Synthesis of 2-Substituted 1-Methylsulfoonylindoles From N-(2-Halophenyl) Methanesulfonamides”, Takao Sakamoto et al., Chem. Pharm. Bull., No. 4, Sep. 1987, pp. 1305-1308.
“An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey”, Jacquelynn J. Cook et al.,Basic Science Reports, Oct. 1994, pp. 2961-2971.
“Protease-Activated Receptor 3 is a Second Thrombin Receptor in Human”, Hiroaki Ishihara, Nature, vol. 386, Apr. 1997, pp. 502-508.
Hoekstra William J.
Maryanoff Bruce E.
McComsey David F.
Zhang Han-Cheng
Lopez Gabrial
Millennium Pharmaceuticals Inc.
Ortho-McNeil Pharmaceutical , Inc.
Riley Jezia
Woodrow Hal B.
LandOfFree
Indole peptidomimetics as thrombin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole peptidomimetics as thrombin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole peptidomimetics as thrombin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443160